Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.
D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ: CLNN) with a Buy and maintains $23 price target.
Benchmark analyst Bruce D. Jackson maintains Clene (NASDAQ:CLNN) with a Buy and lowers the price target from $33 to $31.
- SEC Filing
Novel human preclinical neuronal model for Parkinson's disease demonstrated CNM-Au8's ability to improve mitochondrial ...
D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.
